The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
Schering AG
Advised Bayer on its public offer for Schering, an international pharmaceuticals group based in Berlin, Germany
Wolters Kluwer Education
Advised Bridgepoint Capital Limited on its acquisition of Wolters Kluwer Education, the pan-European educational publishing division of quoted Dutch-based information services and publishing company Wolters Kluwer NV
E. Brost & J. Funke GmbH & Co. KG (BFK KG) and its 25% stake in Otto Group
Advised the shareholders of BFK KG, comprising the families who also own German publisher WAZ Media Group, on the sale of their 25% holding in German retailing and services group Otto to the Otto family, which thereby regained full ownership of the business
Ventana Medical Systems, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of Ventana Medical Systems, Inc., a US based provider of histopathology diagnostic equipment
Genentech, Inc.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
Enzon Pharmaceuticals, Inc.
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
Verivox Holding Limited
Advised the shareholders of Verivox Holdings Limited, comprising Independent News & Media plc and the founders and joint CEOs of Verivox, on the sale of 51% in Verivox, Germany’s leading price comparison website for energy and telecommunications services, to Oakley Capital Private Equity
Media Monitors
Advised Media Monitors, the leading media intelligence company in Asia-Pacific, on its sale to Quadrant Private Equity
Mitchell Communication Group Limited
Advised Aegis Group plc on its acquisition of Mitchell Communication Group Limited, Australia’s leading independent media buyer
Healthcare Australia
Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK
Alcon, Inc.
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
The Synovate Group
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
iNova Pharmaceuticals
Advised Archer Capital and Ironbridge Capital on the sale of iNova Pharmaceuticals, a leading pharmaceuticals company that sells and distributes a range of prescription and over-the-counter products in Australia, New Zealand, Asia and Southern Africa, to Valeant Pharmaceuticals
Aegis Group plc
Advised Aegis Group plc, a leading global media and digital communications agency, on its sale to Dentsu Inc., the leading advertising group in Asia
Broadcast Rights for the National Rugby League
Advised the Australian Rugby League Commission on the sale of the Australian television broadcasting rights for the National Rugby League to Nine, a leading Free to Air broadcaster and Fox Sports, Australia’s largest pay TV broadcaster (partially owned by News Limited)
DMG Radio Australia, a subsidiary of Daily Mail and Guardian Trust Plc
Advised Daily Mail and Guardian Trust plc (DMGT), on the sale of its remaining 50% interest in its Radio business in Australia to Illyria Pty, a private investment company of Lachlan Murdoch. The Radio operations comprise two national music networks in Australia
SKY Network Television Limited
Advised Todd Corporation, a major New Zealand family office, on the divestment of its 11.1% holding in SKY Network Television Limited, New Zealand’s leading provider of pay television services
Broadcast Rights for V8 Supercars
Advised Archer Capital, a leading Australian private equity firm, and its portfolio company V8 Supercars Australia, on the sale of the Australian FTA television broadcasting rights for V8 Supercars to Seven, a leading Free to Air broadcaster in Australia
Warner Chilcott, plc
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
iSelect (30% shareholding)
Advised Mi9, a joint venture between Microsoft and Nine Entertainment Co, and one of Australia’s leading digital media companies, on the sale of its 30% holding in iSelect, a leading Australian online-driven comparison service, as part of the Initial Public Offering of iSelect
Global Television
Advised Catalyst Investment Managers on the sale of its portfolio company Global Television, Australia’s largest provider of outsourced broadcasting and video production services, to NEP Inc., a leading provider of total broadcast solutions in the US, UK and Brazil. NEP is majority-owned by private funds managed by Crestview Partners
Open Colleges Australia Pty Ltd
Advised Open Colleges, Australia’s leading privately owned online provider in the high-growth vocational education and training sector, on the sale of a 70% stake (plus exit arrangements for the balance) to Apollo Education Group, Inc., one of North America’s largest private education providers
Forest Laboratories Inc.
Advised Actavis plc, a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products on its acquisition of Forest Laboratories Inc.
ARTnews
Advised ARTnews, the world's oldest and most widely circulated art magazine, on its sale to Skate Capital Corp., a private art and media industry investment vehicle
Clinuvel Pharmaceuticals Limited
Advised Clinuvel, a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders, in response to an unsolicited proposal to acquire the business from Retrophin, a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases